deepgenomics.comCrawled Nov 3, 2026
Deep Genomics' Biological Foundation Model (BioFM) Platform enables scalable molecular design and target biology discovery.
Insights and stories from the Deep Genomics team.
Information updates and press releases from Deep Genomics.
Deep Genomics introduces its leadership, advisors, and board, who specialize in genomics, drug development, and AI.
Deep Genomics has offices in Toronto and Boston.
Deep Genomics combines AI and biology to discover and design genetic medicines, powered by the BioFM biological foundation model platform.
Deep Genomics outlines its privacy policy for personal information collected through its website and other interactions.
Deep Genomics introduces **Beam**, a proprietary context engine for AI agent security. The platform provides 10-minute visibility into agent operations, real-time behavioral monitoring, and proactive risk management. It is positioned as the global standard for securing enterprise AI agents in 2026.
Feb 2026Global Recognition Awards™News article
Deep Genomics opens a new office and lab in Cambridge, Massachusetts, expanding its Toronto-based operations. The company hires leadership talent to advance its AI-driven RNA therapy platform for genetic diseases. With over 100 employees across AI, molecular biology, and software engineering, Deep Genomics integrates automation and machine learning into drug discovery.
Jun 2024Drug Discovery and DevelopmentNews article
Deep Genomics names **Brian O’Callaghan** as its new CEO to guide the company’s transition into a forward-integrated biopharmaceutical business. O’Callaghan brings extensive global experience in life-science leadership and a history of successful ventures in the sector. The move aligns with Deep Genomics’ strategic shift toward deeper involvement in drug development and commercialization.
Sep 2023Financial PostNews article
Deep Genomics uses AI to identify its first therapeutic drug candidate. The company applies machine learning to accelerate drug discovery by targeting genetic insights. This marks a potential milestone in AI-driven pharmaceutical development.
Sep 2019pharmaphorumNews article